#AACR26 In MATISSE, need to acknowledge the heterogeneity and going forward, should we distinguish N2 vs non-N2? pCR rates of IPH5201 + d...

AACR 2026 现场信号· @ · X·2026-04-22 20:25· 2026-04-22评分60

正文 · 原文

#AACR26 In MATISSE, need to acknowledge the heterogeneity and going forward, should we distinguish N2 vs non-N2? pCR rates of IPH5201 + durva/chemo encouraging, esp in PDL1 high - not far from current options but smaller sample, single arm. https://t.co/It24B5NNZC

热度 3 · 2 赞 · 1 回复 · 0 转发

会议摘要

CT231NCT05742607按代号 IPH5201 对上

Dual CD39 and PD-L1 inhibition: Interim results from the phase 2 MATISSE trial of IPH5201 plus durvalumab (durva) and platinum-based chemotherapy (CT) in patients (pts) with resectable NSCLC

Fabrice Barlesi, Tibor Csoszi, Renata Duchnowska, Thomas Egenod, Laurent Greillier, Amanda Psyrri, Maurice Perol, Herve Lena, Agnes Boyer-Chammard, Veronia Todary, Julien Viotti, Pascale André, Carine Paturel, Markus Jensen

读摘要原文 →

来源：AACR 2026 现场信号 · x.com